Introduction: Ocular medulloepithelioma is a rare intraocular neoplasm which is believed to be of congenital origin but is often diagnosed between 2nd and 10th year of life due to symptomatic presentation. It arises mostly from the ciliary body and carries an excellent overall survival prognosis if not extended extraocular. Primary enucleation has been favored as a first-line treatment option in most cases but in last decades effort has been made to offer globe saving treatment options to patients and families. Experiences from few cases series highlight brachytherapy as most promising treatment option so far which has mostly been utilizing Ruthenium-106 or Iodine-125. We herewith report further results of the use of Ruthenium-106 brachytherapy as globe-salvage attempt in ocular medulloepithelioma. Methods: Retrospective case series and data analysis of 5 eyes in 5 children treated with Ruthenium-106 brachytherapy from 01/2002 to 10/2024. Results: Mean age at treatment was 5 years (11 months–11 years) with a mean tumor thickness of 5.3 mm (2.9–6.7 mm) and a follow-up of 78 months (11–172 months) after treatment. Mean dosage applied for apex and sclera was 82 Gy (70–89 Gy) and 772 (317–1,033 Gy), respectively. Two eyes had to be enucleated after 3 months and 11 years, respectively, whereas histological examination showed no evidence of viable tumor cells. One eye showed recurrence after 34 months which was treated with re-brachytherapy. Most frequent complication was development or worsening of cataract which was successfully operated in 2 eyes. Only two children had a visual acuity of >20/400 (20/50 and 20/80). None of the children showed signs of metastasis, and all children are alive during follow-up period. Conclusion: Ruthenium-106 brachytherapy is an effective treatment modality for ocular medulloepithelioma. Frequency of anterior segment complications was high in our cohort leading to relatively low long-term visual acuity.

1.
de Kock
L
,
Priest
JR
,
Foulkes
WD
,
Alexandrescu
S
.
An update on the central nervous system manifestations of DICER1 syndrome
.
Acta Neuropathol
.
2020
;
139
(
4
):
689
701
.
2.
Kaliki
S
,
Shields
CL
,
Eagle
RC
Jr
,
Vemuganti
GK
,
Almeida
A
,
Manjandavida
FP
, et al
.
Ciliary body medulloepithelioma: analysis of 41 cases
.
Ophthalmology
.
2013
;
120
(
12
):
2552
9
.
3.
Broughton
WL
,
Zimmerman
LE
.
A clinicopathologic study of 56 cases of intraocular medulloepitheliomas
.
Am J Ophthalmol
.
1978
;
85
(
3
):
407
18
.
4.
Verdijk
RM
.
On the classification and grading of medulloepithelioma of the eye
.
Ocul Oncol Pathol
.
2016
;
2
(
3
):
190
3
.
5.
Tadepalli
SH
,
Shields
CL
,
Shields
JA
,
Honavar
SG
.
Intraocular medulloepithelioma: a review of clinical features, DICER 1 mutation, and management
.
Indian J Ophthalmol
.
2019
;
67
(
6
):
755
62
.
6.
Lumbroso
L
,
Desjardins
L
,
Coue
O
,
Ducourneau
Y
,
Pechereau
A
.
Presumed bilateral medulloepithelioma
.
Arch Ophthalmol
.
2001
;
119
(
3
):
449
50
.
7.
Davidorf
FH
,
Craig
E
,
Birnbaum
L
,
Wakely
P
Jr
.
Management of medulloepithelioma of the ciliary body with brachytherapy
.
Am J Ophthalmol
.
2002
;
133
(
6
):
841
3
.
8.
Poon
DS
,
Reich
E
,
Smith
VM
,
Kingston
J
,
Reddy
MA
,
Hungerford
JL
, et al
.
Ruthenium-106 plaque brachytherapy in the primary management of ocular medulloepithelioma
.
Ophthalmology
.
2015
;
122
(
9
):
1949
51
.
9.
Ang
SM
,
Dalvin
LA
,
Emrich
J
,
Komarnicky
L
,
Shields
JA
,
Shields
CL
.
Plaque radiotherapy for medulloepithelioma in 6 cases from a single center
.
Asia Pac J Ophthalmol
.
2019
;
8
(
1
):
30
5
.
10.
Mohan
S
,
Gange
WS
,
Kim
J
,
Sibug Saber
ME
.
Histopathology of intraocular medulloepithelioma following iodine-125 plaque brachytherapy
.
Case Rep Ophthalmol
.
2022
;
13
(
1
):
196
203
.
11.
Ortiz-Seller
A
,
Martínez-Costa
R
,
Calatayud
JP
,
Palacios
IA
,
Hernández
AR
,
González
HB
.
Ciliary body medulloepithelioma treated with intra-operative brachytherapy after fine needle aspiration biopsy
.
J Contemp Brachytherapy
.
2022
;
14
(
3
):
273
7
.
12.
Bechrakis
NE
,
Müller-Stolzenburg
NW
,
Helbig
H
,
Foerster
MH
.
Sympathetic ophthalmia following laser cyclocoagulation
.
Arch Ophthalmol
.
1994
;
112
(
1
):
80
4
.
13.
Ahmad
N
,
Soong
TK
,
Salvi
S
,
Rudle
PA
,
Rennie
IG
.
Sympathetic ophthalmia after ruthenium plaque brachytherapy
.
Br J Ophthalmol
.
2007
;
91
(
3
):
399
401
.
You do not currently have access to this content.